<sup>18</sup>F-AlF-NOTA-Octreotide Outperforms<sup>68</sup>Ga-DOTATATE/NOC PET in Neuroendocrine Tumor Patients: Results from a Prospective, Multicenter StudyElin Pauwels, Christophe M. Deroose, Annouschka Laenen et al.|Journal of Nuclear Medicine|2022Cited by 74
Inflammation-Based Index and <sup>68</sup>Ga-DOTATOC PET–Derived Uptake and Volumetric Parameters Predict Outcome in Neuroendocrine Tumor Patients Treated with <sup>90</sup>Y-DOTATOCElin Pauwels, Christophe M. Deroose, Sofie Van Binnebeek et al.|Journal of Nuclear Medicine|2019Cited by 44
[18F] MFBG PET imaging: biodistribution, pharmacokinetics, and comparison with [123I] MIBG in neural crest tumour patientsElin Pauwels, Christophe M. Deroose, Sofie Celen et al.|European Journal of Nuclear Medicine and Molecular Imaging|2022Cited by 23
[<sup>68</sup>Ga]Ga-DOTATATE-avid tumor volume, uptake and inflammation-based index correlate with survival in neuroendocrine tumor patients treated with [<sup>177</sup>Lu]Lu-DOTATATE PRRT.Elin Pauwels, Christophe M. Deroose, Jeroen Dekervel et al.|PubMed|2022Cited by 11
Early Whole-Body Diffusion-weighted MRI Helps Predict Long-term Outcome Following Peptide Receptor Radionuclide Therapy for Metastatic Neuroendocrine TumorsVincent Vandecaveye, Christophe M. Deroose, Raphaëla C. Dresen et al.|Radiology Imaging Cancer|2022Cited by 7